Special Issue "Anti-Cancer and Other Health-Promoting Effects of Silibinin and Silibinin Derivatives"

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Natural Products".

Deadline for manuscript submissions: 31 December 2021.

Special Issue Editors

Dr. Javier A. Menendez
E-Mail Website1 Website2
Guest Editor
1. Program Against Cancer Therapeutic Resistance (ProCURE), Metabolism and Cancer Group, Catalan Institute of Oncology, Girona, Spain
2. Girona Biomedical Research Institute (IDIBGI), Girona, Spain
Interests: cancer; metabolism; bioactive compounds
Dr. Joaquim Bosch-Barrera
E-Mail Website
Guest Editor
1. Medical Oncology, Catalan Institute of Oncology, 17007 Girona, Catalonia, Spain
2. Girona Biomedical Research Institute (IDIBGI), 17190 Girona, Catalonia, Spain
3. Department of Medical Sciences, Medical School, University of Girona, 17071 Girona, Spain
Interests: lung cancer; brain metastasis; bioactive compounds
Dr. Elisabet Cuyàs Navarro
E-Mail Website
Guest Editor
1. Program Against Cancer Therapeutic Resistance (ProCURE), Metabolism and Cancer Group, Catalan Institute of Oncology, Girona, Spain;
2. Girona Biomedical Research Institute (IDIBGI), Girona, Spain
Interests: cancer; metabolism; bioactive compounds

Special Issue Information

Dear Colleagues,

The flavonolignan silibinin (or silybin) is considered the major bioactive component of silymarin, an extract of Silybum marianum (milk thistle) seeds that was classified by the World Health Organization in the 1970s as an official medicine with health-promoting properties. The well-known hepatoprotective, anti-inflammatory, and anti-fibrotic effects of silibinin have supported the therapeutic use of silymarin for the treatment of liver illnesses such as alcoholic liver disease, nonalcoholic liver disease, drug-induced liver injury, cirrhosis, viral hepatitis, and mushroom poisoning over the last 50 years.

 

In the last decade, an ever-growing number of preclinical studies have illuminated the potential anti-cancer effects of silibinin. Silibinin has been shown to exert significant tumoricidal activity against cultured cancer cells and xenografts, to enhance the efficacy of other anti-cancer therapeutic agents, to reduce the toxicity of cancer treatments, and to prevent and overcome the emergence of cancer drug resistance. However, the achievement of a bona fide, clinically relevant anti-cancer activity of silibinin remains controversial in human trials. Thus, whereas no significant anti-tumor activity of silibinin has been reported in prostate cancer tissues, certain silibinin-containing formulations have been successfully applied to lung cancer patients with established brain metastases, providing highly significant survival advantages, low toxicity and reversible secondary effects, and compatibility with the standard-of-care.

 

To encompass the remarkable breadth of ongoing investigation on silibinin and cancer, research articles, review articles as well as short communications covering a wide range of topics related to the therapeutic application of silibinin as an anti-cancer treatment, including but not limited to molecular mechanisms, signaling pathways, metabolism, pre-clinical studies, drug formulations, analogues, drug combinations, immune response, and clinical trials are welcomed for inclusion in this Special Issue of Pharmaceuticals. Manuscripts reporting on the health-promoting effects and molecular bases of silibinin (or other components of silymarin and its derivatives) for aging-related chronic diseases such as obesity, type 2 diabetes, metabolic syndrome, chronic respiratory diseases, cardiovascular diseases, neurodegenerative diseases, as well as viral infections including SARS-CoV-2/COVID-19 will also be welcomed in the issue.

Dr. Javier A. Menendez
Dr. Joaquim Bosch-Barrera
Dr. Elisabet Cuyàs Navarro
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • silibinin (or silybin)
  • Silymarin and Derivatives
  • Molecular mechanisms of action
  • Cellular mechanisms of action
  • Metabolism and bioavailability
  • Drug development
  • Analogs
  • Pre-clinical studies
  • Metastasis
  • Immune system
  • Clinical trials
  • Epidemiology
  • Obesity
  • Type 2 diabetes
  • Metabolic syndrome
  • Chronic respiratory diseases
  • Chronic obstructive pulmonary disease
  • Asthma
  • Pulmonary hypertension
  • Cardiovascular disease
  • Myocardial infarction
  • Hypertension
  • Neurogenerative diseases
  • Amyotrophic lateral sclerosis
  • Parkinson’s diseases
  • Alzheimer’s disease
  • Huntington’s disease
  • Viral infections
  • HIV
  • SARS-CoV2
  • COVID-19

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

Review
Lung Cancer Management with Silibinin: A Historical and Translational Perspective
Pharmaceuticals 2021, 14(6), 559; https://0-doi-org.brum.beds.ac.uk/10.3390/ph14060559 - 11 Jun 2021
Viewed by 807
Abstract
The flavonolignan silibinin, the major bioactive component of the silymarin extract of Silybum marianum (milk thistle) seeds, is gaining traction as a novel anti-cancer therapeutic. Here, we review the historical developments that have laid the groundwork for the evaluation of silibinin as a [...] Read more.
The flavonolignan silibinin, the major bioactive component of the silymarin extract of Silybum marianum (milk thistle) seeds, is gaining traction as a novel anti-cancer therapeutic. Here, we review the historical developments that have laid the groundwork for the evaluation of silibinin as a chemopreventive and therapeutic agent in human lung cancer, including translational insights into its mechanism of action to control the aggressive behavior of lung carcinoma subtypes prone to metastasis. First, we summarize the evidence from chemically induced primary lung tumors supporting a role for silibinin in lung cancer prevention. Second, we reassess the preclinical and clinical evidence on the effectiveness of silibinin against drug resistance and brain metastasis traits of lung carcinomas. Third, we revisit the transcription factor STAT3 as a central tumor-cell intrinsic and microenvironmental target of silibinin in primary lung tumors and brain metastasis. Finally, by unraveling the selective vulnerability of silibinin-treated tumor cells to drugs using CRISPR-based chemosensitivity screenings (e.g., the hexosamine biosynthesis pathway inhibitor azaserine), we illustrate how the therapeutic use of silibinin against targetable weaknesses might be capitalized in specific lung cancer subtypes (e.g., KRAS/STK11 co-mutant tumors). Forthcoming studies should take up the challenge of developing silibinin and/or next-generation silibinin derivatives as novel lung cancer-preventive and therapeutic biomolecules. Full article
Show Figures

Graphical abstract

Back to TopTop